March 18, 2022
Ginkgo Bioworks Signs Definitive Agreement to Acquire FGen AG, a Leading Bioengineering Company and its Proprietary Ultra-high-throughput Screening Platform
Ginkgo Bioworks has announced the entry into a definitive agreement to acquire FGen AG (“FGen”), a Swiss company specializing in strain development and optimization.